1. Volume 62, Issue 5, Pages 757-764 (November 2012)
Serum Testosterone and Dihydrotestosterone and Prostate Cancer Risk in the Placebo Arm of the Reduction by Dutasteride of Prostate Cancer Events Trial 
Roberto L. Muller, Leah Gerber, Daniel M. Moreira, Gerald Andriole, Ramiro Castro-Santamaria, Stephen J. Freedland 
European Urology 
Volume 62, Issue 5, Pages (November 2012)
DOI: /j.eururo
Copyright © 2012 European Association of Urology Terms and Conditions

2. Fig. 1
Assembly of our study population. PCa=prostate cancer; REDUCE=Reduction by Dutasteride of Prostate Cancer Events; BMI=body mass index; TRUS=transrectal ultrasound; DHT=dihydrotestosterone; DRE=digital rectal examination; PSA=prostate-specific antigen.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

3. Fig. 2
Locally weighted scatterplot smoothing of serum levels of testosterone and dihydrotestosterone (DHT) at baseline and final cancer status after considering all biopsies during 4 yr of the REDUCE trial. The overlapping circles on the top and bottom of the chart represent each individual case. Men detected with prostate cancer were coded as 1, whereas men with no prostate cancer detected were coded as 0.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions